Jim Simons’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Jim Simons’s Portfolio NDRM Stock Details NDRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-106,500	Closed	-$4.14M	–	3677
2017 Q3	$4.14M	Buy	+106,500	New	+$3.92M	﹤0.01%	1885
2017 Q2	–	Sell	-79,626	Closed	-$2.11M	–	3570
2017 Q1	$2.11M	Sell	79,626 -1,316	-2%	-$32.6K	﹤0.01%	2207
2016 Q4	$1.8M	Buy	+80,942	New	+$1.51M	﹤0.01%	2281

Other funds holding NDRM

VOAM

Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

FWM

Focused Wealth Management Newburgh, New York $1.15B AUM 24.81% 1-Year Est. Return

Jim Simons's NDRM Position: Q4 2017 in Review

Jim Simons sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q4 2017, closing a stake of 106,500 shares — an estimated $4.14M sold.

Jim Simons first reported a position in NDRM in Q4 2016 and held it in 3 quarters. The position peaked at $4.14M in Q3 2017. 5 funds tracked by Wall St. Rank hold NDRM as of Q4 2017.

Jim Simons reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q4 2017 after selling out during the quarter.
Jim Simons sold 106,500 NeuroDerm Ltd. Ordinary Shares shares in Q4 2017, an estimated $4.14M.
Jim Simons first reported a position in NeuroDerm Ltd. Ordinary Shares in Q4 2016 and held it in 3 quarters.
Jim Simons's NeuroDerm Ltd. Ordinary Shares position peaked at $4.14M in Q3 2017.
5 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q4 2017.

Based on Renaissance Technologies's 13F filing for Q4 2017, filed 13 Feb 2018.